Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 21, 2025 • 12:00 AM ET

Date/Time Source News Release
06/18/2025 09:15 AM EDT ACCESS Newswire Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging
06/11/2025 09:30 AM EDT ACCESS Newswire Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model
06/05/2025 08:30 AM EDT ACCESS Newswire Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
06/02/2025 08:30 AM EDT ACCESS Newswire Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform
05/29/2025 08:30 AM EDT ACCESS Newswire Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints
05/21/2025 09:00 AM EDT ACCESS Newswire Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND
05/15/2025 08:00 AM EDT ACCESS Newswire Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity
05/07/2025 08:00 AM EDT ACCESS Newswire Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia
03/19/2025 08:00 AM EDT ACCESS Newswire Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells
02/26/2025 08:00 AM EST ACCESS Newswire Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
Page

Additional News

As of June 21, 2025 • 12:00 AM ET

Date/Time Source News Release
06/18/2025 12:09 PM EDT BioMedWire BioMedNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success for Telomir-1 in Progeria Cell Lines 
06/11/2025 10:10 AM EDT InvestorWire InvestorNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Breakthrough with Telomir-1 in Wilson's Disease Model
06/05/2025 09:45 AM EDT InvestorWire InvestorNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Breakthrough in Age-Reversal Model With Telomir-1
06/02/2025 09:35 AM EDT InvestorWire InvestorNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO) to Pursue Partnerships at BIO 2025 as IND Prep for Telomir-1 Advances
05/29/2025 11:20 AM EDT InvestorWire InvestorNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO) Reports Vision Restoration and Retinal Regeneration in Preclinical AMD Study
05/21/2025 10:05 AM EDT InvestorWire InvestorNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO) Secures $3M Equity Investment to Advance Age-Reversal Pipeline
05/21/2025 09:11 AM EDT SeekingAlpha Telomir Pharmaceuticals secures $3M in straight equity sale
05/15/2025 10:10 AM EDT BioMedWire BioMedNewsBreaks - Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Silver(II) Antimicrobial Drug Candidate Telomir-Ag2
05/12/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, May 12th, 2025
05/12/2025 05:31 AM EDT US Earnings Reports Expected earnings - Telomir Pharmaceuticals Inc.
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.